NDA 021450 · Amneal
Zomig
Zolmitriptan · Nasal · Serotonin-1b and Serotonin-1d Receptor Agonist
Last checked: Nov 20, 2026Latest source record: Dec 21, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Sep 30, 2003
Approved uses
4
Original approval plus efficacy supplements
Registered trials
22
7 Phase 3, 0 recruiting
FAERS reports
7,229
4,645 serious, 172 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 30, 2019.
ZOLMITRIPTAN NASAL SPRAY is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. Limitations of Use Only use ZOLMITRIPTAN NASAL SPRAY if a clear diagnosis of migraine has been established. If a patient has no response to ZOLMITRIPTAN NASAL SPRAY treatment for the first migraine attack, reconsider the diagnosis of migraine before ZOLMITRIPTAN NASAL SPRAY is administered to treat any subsequent attacks. ZOLMITRIPTAN NASAL SPRAY is not indicated for the prevention of migraine attacks. Safety and effectiveness of ZOLMITRIPTAN NASAL SPRAY have not been established for cluster headache. Not recommended in patients with moderate or severe hepatic impairment [see Dosage and Administration (2.2) ] . ZOLMITRIPTAN NASAL SPRAY is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years and older (1) Limitations of Use: Use only after a clear diagnosis of migraine has been established (1) Not intended for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1) Not recommended in patients with moderate to severe hepatic impairment (1)
Mechanism: Zolmitriptan binds with high affinity to human recombinant 5-HT 1D and 5-HT 1B receptors, and moderate affinity for 5-HT 1A receptors. The N-desmethyl metabolite also has high affinity for 5-HT 1B/1D and moderate affinity for 5-HT1A receptors. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 12, 2015 Supplement 8 · Efficacy LetterLabel
- Sep 16, 2013 Supplement 7 · Efficacy LabelLetter
- Oct 14, 2008 Supplement 5 · Efficacy Letter
- Sep 30, 2003 Original approval · Type 3 - New Dosage Form Pediatric Medical ReviewPediatric Statistical ReviewPediatric Medical Review
2 products under this application
- ZOMIG · ZOLMITRIPTAN 5MG/SPRAY · SPRAY, NASAL · Prescription · TE AB
- ZOMIG · ZOLMITRIPTAN 2.5MG/SPRAY · SPRAY, NASAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Zolmitriptan" as an intervention, any sponsor and status, largest first.
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- Efficacy and Tolerability of Zolmitriptan Nasal SprayPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00617747 · 2,114 participants · Start Sep 2002
Drug: Zolmitriptan; Placebo · For: Migraine
- Zomig - Treatment of Acute Migraine Headache in AdolescentsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01211145 · 1,653 participants · Start Sep 2010 · Primary completion Oct 2013
Drug: Placebo; Zolmitriptan and 2 more · For: Migraine Headache
Sites: Phoenix, Arizona; Fresno, California; Fullerton, California · 74 sites in all
- Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00442936 · 1,380 participants · Start Feb 15, 2007 · Primary completion Oct 2, 2007
Drug: Telcagepant potassium 150 mg; Telcagepant potassium 300 mg and 5 more · For: Migraine
- Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLEPivotal-lookingCompleted
Impax Laboratories, LLCIndustry
NCT03275922 · 374 participants · Start Nov 27, 2017 · Primary completion Jul 2, 2020
Drug: Placebo ZNS; ZNS · For: Migraine
Sites: Phoenix, Arizona; Little Rock, Arkansas; Anaheim, California · 47 sites in all
- Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of MigrainePivotal-lookingCompleted
Zosano Pharma CorporationIndustry
NCT02745392 · 365 participants · Start Jun 2016 · Primary completion Jan 2017
Drug: ZP-Zolmitriptan; Placebo · For: Acute Migraine
Sites: Glendale, Arizona; Carlsbad, California; Huntington Beach, California · 36 sites in all
- A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of MigrainePivotal-lookingCompleted
Zosano Pharma CorporationIndustry
NCT03282227 · 342 participants · Start Nov 7, 2017 · Primary completion May 17, 2019
Drug: M207 Microneedle System · For: Migraine
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 31 sites in all
- Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in AdolescentsPivotal-lookingCompleted
Impax Laboratories, LLCIndustry
NCT00617695 · 247 participants · Start Sep 2003
Drug: Zolmitriptan; Placebo · For: Migraine
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- migraine1,032
- headache954
- drug ineffective755
- nausea559
- off label use558
- fatigue485
- pain431
- drug intolerance367
- vomiting348
- dizziness339
- malaise301
- dyspnoea290
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 116 |
| 2005 | 112 |
| 2006 | 120 |
| 2007 | 154 |
| 2008 | 166 |
| 2009 | 176 |
| 2010 | 207 |
| 2011 | 348 |
| 2012 | 658 |
| 2013 | 224 |
| 2014 | 267 |
| 2015 | 259 |
| 2016 | 407 |
| 2017 | 386 |
| 2018 | 388 |
| 2019 | 528 |
| 2020 | 477 |
| 2021 | 400 |
| 2022 | 377 |
| 2023 | 383 |
| 2024 | 396 |
| 2025 | 390 |
| 2026 | 290 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zomig* (Zolmitriptan)
2024 spending
$255K
Beneficiaries
90
202 claims
Per beneficiary
$2,829
$93.86 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,491,165 |
| 2021 | $6,361,555 |
| 2022 | $2,963,029 |
| 2023 | $1,272,976 |
| 2024 | $254,577 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.
Karlsson WK, Ostinelli EG, Zhuang ZA, et al. · BMJ 2024 · Systematic Review, Comparative Study
- Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis.
Gerolymos C, Barazer R, Yon DK, et al. · JAMA Netw Open 2024 · Systematic Review, Network Meta-Analysis
- Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
Oskoui M, Pringsheim T, Holler-Managan Y, et al. · Neurology 2019 · Practice Guideline, Research Support, Non-U.S. Gov't
- Cluster headache.
Matharu M, Silver N · BMJ Clin Evid 2008 · Systematic Review
- Cluster headache.
Matharu M · BMJ Clin Evid 2010 · Systematic Review
- Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
Cameron C, Kelly S, Hsieh SC, et al. · Headache 2015 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Amneal
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.